A Non-interventional Biomarker Study in Patients With Non-Small Cell Lung Cancer (NSCLC) of Adenocarcinoma Tumour Histology Eligible for Treatment With Vargatef® According to the Approved Label.
Phase of Trial: Phase IV
Latest Information Update: 11 Aug 2017
At a glance
- Drugs Nintedanib (Primary)
- Indications Non-small cell lung cancer
- Focus Biomarker; Therapeutic Use
- Acronyms LUME BioNIS
- Sponsors Boehringer Ingelheim
- 05 Sep 2016 Planned End Date changed from 1 Apr 2020 to 1 Nov 2020.
- 21 Mar 2016 Status changed from not yet recruiting to recruiting, according to ClinicalTrials.gov record.
- 08 Mar 2016 Planned initiation date changed from 1 Feb 2016 to 1 Mar 2016 as reported by ClinicalTrials.gov.